ABDM is a critical integration that leverages an open, interoperable, standards-based digital system that is secure, and maintains confidentiality and privacy of health-related personal information
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
The plant is expected to start commercial operations from Q4FY24
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
Revolution Aspire CT System is manufactured at the company’s new plant launched under the government’s Production Linked Incentives (PLI) Scheme
These bulk orders will contribute to the topline of the company as well as help in improving EBITDA of the company
Subscribe To Our Newsletter & Stay Updated
